Respiratory & Immunology

Following the science to improve patient outcomes

Building on a 50-year heritage in respiratory care, our ambition is to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by driving earlier, biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.

Underpinning chronic lung diseases is an altered immune system. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas.


Advancing the science of Respiratory & Immunology for patients

How can we make the biggest possible difference for patients? Hear from the team at AstraZeneca who are working to advance cutting-edge science and our growing pipeline in Respiratory and Immunology.




Our people


Join Our Team


At AstraZeneca Respiratory & Immunology, we’re driven by innovation and our commitment to make a real-life difference in patients’ lives. That difference starts with you. As one of Science Magazine’s 2018 Top Employer, we need people like you who share our passion for science and determination to meet patients’ needs around the world.




Our Pipeline


Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.


Respiratory & Immunology (as at 29 April 2020)

Phase I

Phase I

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma
  • MEDI5117 China rheumatoid arthritis

Phase II

Phase II

  • abediterol asthma/chronic obstructive pulmonary disease
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • MEDI3506 chronic obstructive pulmonary disease and atopic dermatitis
  • navafenterol (AZD8871) chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease
  • velsecorat (AZD7594) asthma/chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumab TULIP systemic lupus erythematosus
  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • Breztri Aerosphere (PT010) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri (PT010) asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyposis
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma



Our Medicines


We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations.

Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.


Accolate, Accoleit, Vanticon

zafirlukast

Bevespi Aerosphere

glycopyrronium/formoterol fumarate

Breztri Aerosphere

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules

365备用网址APPterbutaline

Bricanyl Turbuhaler

365备用网址APPterbutaline in a dry powder inhaler

Daliresp/Daxas

roflumilast

Duaklir Genuair

aclidinium/formoterol

Eklira Genuair/Tudorza/Bretaris

365备用网址APPaclidinium, a LAMA

Fasenra

benralizumab

Oxis Turbuhaler

Oxis Turbuhaler

Pulmicort Respules

budesonide inhalation suspension

Pulmicort Turbuhaler

budesonide

Rhinocort

budesonide

Symbicort pMDI

365备用网址APPbudesonide/formoterol

Symbicort Turbuhaler

budesonide/formoterol


Latest news



Veeva ID: Z4-23796

Date of next review: April 2022